Oracle's Two Faces: A $638 Billion Backlog Meets a Brussels Inquiry

Oracle reports Q1 fiscal 2027 results as the EU Commission gathers input on its licensing practices and investors weigh AI growth against financing costs.

Oracle reports first-quarter fiscal 2027 results after the U.S. close tonight, and for the AI infrastructure trade broadly, the stakes could hardly be higher. Reuters has framed the release as a potential bellwether for the entire hyperscaler complex. Yet while the market fixates on the numbers due at 11 p.m. German time, a quieter story is unfolding in Brussels — one that speaks to the less glamorous side of Oracle's resurgence.

According to media reports, the European Commission is gathering information from third parties regarding Oracle's software licensing practices. Reuters first flagged the outreach on September 1 and repeated the report a week later, on Tuesday. No formal investigation has been opened; the Commission is simply collecting input. On its face, that reads like administrative housekeeping.

It is not quite so mundane when you consider how central licensing models have been to Oracle's business for decades — and how often that very topic has stirred trouble in Europe before.

Two narratives, one ticker

What makes this juxtaposition so telling? On one side stands a company placing multibillion-dollar wagers on cloud and AI infrastructure, its share price tethered to each quarterly report like a thermometer. On the other sits an antitrust theme that harks back to the old Oracle: software licenses, maintenance contracts, a business model conceived long before the cloud era. Both storylines converge on the same stock right now, and that is rarely coincidental — it reveals how thoroughly Oracle has become two companies in one.

The share price itself offers a clue to the market's pre-earnings jitters. The stock currently trades at EUR 134.06, down 3.5% on the day — a taste of the anticipation that has built ahead of the release.

For context: the paper sits 55% below its 52-week high of EUR 294.85, reached last September. That is no ordinary correction; it is a fundamental erosion of confidence accumulated over months.

The price of scale

Observers say investors are focused on two questions above all: how fast the cloud business is truly growing, and how Oracle intends to finance its enormous data-center buildout. Those financing concerns have shaped the weekly outlook since the start of September. A company sinking gigantic sums into infrastructure to capture AI demand must also be able to pay for those bets — and the market is increasingly asking where the money will come from.

Sentiment on the capital markets has long since split. Jefferies analyst Brent Thill trimmed his price target on September 2 from $320 to $290, keeping his Buy rating. The same day, Bernstein SocGen reaffirmed its Outperform rating with a $325 target. A day earlier, TD Cowen had cut far more aggressively, from $300 to $240, while also maintaining a buy recommendation.

Three houses, three different levels of anxiety — yet all fundamentally sticking with their positive ratings. That says something about the ambivalence greeting Oracle right now: nobody doubts the structural AI trend, but everyone is asking what it costs.

What the backlog really shows

And that bill is real. The order reserve (RPO) recently stood at $638 billion, up 363% year over year. For comparison, expected revenue for the current fiscal year is around $90 billion. The backlog is thus nearly seven times the annual revenue Oracle can actually recognize over the next twelve months. Only about 12% of it is expected to convert into real revenue in the coming year. Impressive — and precisely why it is so vulnerable to disappointment.

Free cash flow has been negative for five consecutive quarters; in fiscal 2026, the deficit reached $23.7 billion, against operating cash flow of $32 billion and investments of $55.6 billion. For the current fiscal year, Oracle plans net investments of $70 billion to $95 billion, plus roughly $40 billion in additional debt and equity financing, including a $20 billion share issuance.

Guggenheim, among the more optimistic houses despite a $400 price target, views this dilution as a bigger risk than concentration on individual large customers like OpenAI. That is notable, because it shows even convinced bulls are urging caution on the capital structure.

The OpenAI anchor

Speaking of concentration: in July, OpenAI signed a compute contract with Oracle worth $300 billion over five years — a central pillar of the backlog. That OpenAI has now raised its global forecast for computing spending through 2030 to roughly $750 billion argues for sustained demand. At the same time, it makes Oracle more dependent on a single partner whose own financing situation remains opaque.

Before the release, consensus stood at roughly $1.74 in earnings per share and $19.13 billion in revenue for the first quarter of fiscal 2027 — a 28% year-over-year increase. Oracle's own cloud revenue guidance points to 58% to 64% growth, while for OCI, the infrastructure business, some houses like Jefferies see gains of as much as 115%. The options market is pricing a move of around 11% for tomorrow — in either direction.

That expectation gap, in my view, also explains why the stock remains under pressure despite massive growth. The current price of EUR 138.12 sits roughly 53% below the 52-week high of September 10, 2025. While the paper has recovered 9.5% over the past 30 days, the annual tally remains sharply negative at minus 17%. The market has long since priced in the growth promise — and is now asking who foots the bill.

Wall Street's split verdict

The analyst landscape remains broadly bullish: 26 buy recommendations stand against four hold ratings, with an average price target of $257.59 implying considerable upside. But the range of targets — from $190 at RBC to $400 at Guggenheim — shows how differently the risk is assessed.

Neither opportunity nor risk clearly dominates tonight. The growth figures should remain impressive, but whether they outweigh the financing burden and dilution worries will only be settled by this evening's numbers — and above all by the guidance Oracle attaches to them. The Brussels inquiry will not decide that. It does, however, serve as a reminder that Oracle is not merely an AI contender but also a software company with a long, sometimes uncomfortable history in the licensing business. Both chapters continue in parallel today — one quietly in a Brussels file folder, the other loudly, after the close, on a conference call at 11 p.m. German time.